Press Release
Category Added in a WPeMatico Campaign
-
Arbiter Acquires Vertical Raise to Expand Fundraising Support for Schools and Communities
SANDY, Utah, April 1, 2026 /PRNewswire/ — Arbiter, the unified platform for K–12 athletics and activities management, today announced its…
Read More » -
Arbiter Acquires Vertical Raise to Expand Fundraising Support for Schools and Communities
SANDY, Utah, April 1, 2026 /PRNewswire/ — Arbiter, the unified platform for K–12 athletics and activities management, today announced its…
Read More » -
ADP National Employment Report: Private Sector Employment Increased by 62,000 Jobs in March; Annual Pay was Up 4.5%
ROSELAND, N.J., April 1, 2026 /PRNewswire/ — Private sector employment increased by 62,000 jobs in March and pay was up…
Read More » -
Arbiter Acquires Vertical Raise to Expand Fundraising Support for Schools and Communities
SANDY, Utah, April 1, 2026 /PRNewswire/ — Arbiter, the unified platform for K–12 athletics and activities management, today announced its…
Read More » -
ADP National Employment Report: Private Sector Employment Increased by 62,000 Jobs in March; Annual Pay was Up 4.5%
ROSELAND, N.J., April 1, 2026 /PRNewswire/ — Private sector employment increased by 62,000 jobs in March and pay was up…
Read More » -
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure…
Read More » -
ADP National Employment Report: Private Sector Employment Increased by 62,000 Jobs in March; Annual Pay was Up 4.5%
ROSELAND, N.J., April 1, 2026 /PRNewswire/ — Private sector employment increased by 62,000 jobs in March and pay was up…
Read More » -
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure…
Read More » -
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure…
Read More »
